Yonghong Wan

Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors.

Role of dendritic cell-derived cytokines in immune regulation.

Dendritic cell-derived IL-12 is not required for the generation of cytotoxic, IFN-gamma-secreting, CD8(+) CTL in vivo.

Adenoviral-mediated gene transfer of lymphotactin to the lungs of mice and rats results in infiltration and direct accumulation of CD4+, CD8+, and NK cells.

High-dimensional architectures from the self-assembly of lanthanide ions with benzenedicarboxylates and 1,10-phenanthroline.

A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.

TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection.

Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin.

CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.

T-cell-mediated inflammation does not contribute to the maintenance of airway dysfunction in mice.

Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines.

Recombinant adenovirus vaccines can successfully elicit CD8+ T cell immunity under conditions of extreme leukopenia.

Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts.

The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity.

Cigarette smoke impairs NK cell-dependent tumor immune surveillance.

On the role of CD4+ T cells in the CD8+ T-cell response elicited by recombinant adenovirus vaccines.

Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope.

Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL.

Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells.

Enhanced protein expression by internal ribosomal entry site-driven mRNA translation as a novel approach for in vitro loading of dendritic cells with antigens.

The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector.

Mucosally delivered dendritic cells activate T cells independently of IL-12 and endogenous APCs.

CD4+ T-cell-mediated anti-tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis.

Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination.

Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity.

Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.

Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells.

Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus.

Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses.

Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen.

Potentiating cancer immunotherapy using an oncolytic virus.

CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells.

Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy.

Tolerogenic dendritic cells and their potential applications.

IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells.

Engineering dendritic cells to enhance cancer immunotherapy.

Combined mTOR Inhibition and OX40 Agonism Enhances CD8(+) T Cell Memory and Protective Immunity Produced by Recombinant Adenovirus Vaccines.

ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic.

Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients.

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses.

Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation.

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8 T-cell responses to anticancer vaccines.

Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.

Maraba virus as a potent oncolytic vaccine vector.

Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.

Cell-free tumor microparticle vaccines stimulate dendritic cells via cGAS/STING signaling.

Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity.

T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.

S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3.

High Physiological Concentrations of Progesterone Reverse Estradiol-Mediated Changes in Differentiation and Functions of Bone Marrow Derived Dendritic Cells.

Estradiol Enhances CD4+ T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce Th17 Responses via an IL-1-Dependent Pathway.

Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination.

Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy.

Enhanced Antitumor Immunity Elicited by Dendritic Cell Vaccines Is a Result of Their Ability to Engage Both CTL and IFNγ-producing NK Cells.

Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.

Customized Viral Immunotherapy for HPV-Associated Cancer.

A Pck1-directed glycogen metabolic program regulates formation and maintenance of memory CD8 T cells.

Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer.

Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.

Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.

Development and applications of oncolytic Maraba virus vaccines.

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.

Endogenous T cells prevent tumor immune escape following adoptive T cell therapy.

Ketogenesis-generated β-hydroxybutyrate is an epigenetic regulator of CD8 T-cell memory development.

A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy.

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning.

De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors.

A Transit Time-Resolved Microflow Cytometry-Based Agglutination Immunoassay for On-Site C-Reactive Protein Detection.